Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer

By sjmartinez • March 29, 2025

Bardia A, Pistilli B, Rugo H. Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer. J Clin Oncol. 2025 Mar 28:JCO2402833. doi: 10.1200/JCO-24-02833. Epub ahead of print. PMID: 40153734.

Tags: Hematology/Oncology, Publications

Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer

Moghanaki D, Cameron EA, Garon EB. Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer. Lung Cancer. 2025 Jun[...]

Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer

Bardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta[...]

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A.[...]